Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year-Old Woman as Husband Donates Kidney
Multidisciplinary team manages APLA-related clotting risk and donor-specific antibodies through pre-transplant plasmapheresis, IVIg, and planned anticoagulation
Srinagar, September 2026 : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid Antibody Syndrome (APLA), a serious autoimmune disorder that significantly increases the risk of potentially life-threatening blood clots, who also had Donor Specific Antibodies (DSA) resulting from previous sensitisation.
The transplant, performed on 18 August 2026, involved an ABO-compatible kidney donated by the woman’s husband and required extensive preparation to manage the risk of blood clotting as well as potential immunological complications.
The patient, Mrs. Morifat Rashid, was diagnosed with APLA secondary to Systemic Lupus Erythematosus (SLE) around 1.5 years ago and subsequently developed Chronic Kidney Disease (CKD). She was being treated with warfarin for her increased tendency for blood clotting. Her medical history of three abortions and multiple blood transfusions had also contributed to sensitisation and the presence of DSA, adding a second major challenge to the transplant.
A multidisciplinary team at Yashoda Medicity, comprising Dr. Vaibhav Saxena, Senior Director, Urology, Uro-Oncology, Robotics & Renal Transplant; Dr. Kuldeep Aggarwal, Associate Director, Urology, Uro-Oncology, Robotics & Renal Transplant; Dr. Prajit Mazumdar, Senior Consultant, Nephrology & Renal Transplant; and Dr. Indrajit G. Momin, Senior Consultant, Nephrology & Renal Transplant, planned the procedure to address both risks before transplantation.
To reduce the risk associated with DSA, Mrs. Rashid underwent three sessions of plasmapheresis along with IVIg therapy before the transplant. To manage the risk of thrombosis associated with APLA, her regular warfarin was stopped five days before transplantation and anticoagulation was managed with heparin.
Dr. Vaibhav Saxena, Senior Director, Urology, Uro-Oncology, Robotics & Renal Transplant at Yashoda Medicity, said , “This was a technically challenging transplant given the patient’s high risk of thrombosis. Maintaining blood flow through the transplanted kidney was critical, so the team carefully planned the timing of anticoagulation around surgery and close postoperative monitoring. The good urine output and stable graft function following the procedure reflect the
